LBRX

LB Pharmaceuticals is a clinical-stage biotech whose entire enterprise value rides on a single asset, LB-102, for which the 10-K explicitly flags uncertain 'timing, progress, potential registrational quality, and results' of trials, plus 'ability to obtain funding' to complete development. The company has no commercial revenue (FY2025 revenue is blank in the data), generated a -$25.2M net loss with -$35.2M of operating cash burn, and IPO'd on Nasdaq on September 11, 2025 — which explains the +988% jump in cash to $250M and the +833% jump in total assets. Everything on the balance sheet is IPO proceeds, not operating progress.

The quality of the balance sheet is the only genuinely strong number: $250M cash, $11.6M total liabilities, 0.04x liabilities/equity, $308M current assets vs $7.4M current liabilities. At ~$35M annual burn that is roughly 6-7 years of runway if burn stays flat — but the MD&A telegraphs that burn will rise as LB-102 advances through clinical trials and manufacturing scale-up ('plan to incorporate improvements to enhance commercial scalability'), and R&D actually fell -67% YoY to $16.7M, which is unusually low for a Phase-stage CNS asset and suggests spend will step up materially, shortening runway.